| scholarly article | Q13442814 |
| P2093 | author name string | D Martin | |
| N Cadieux | |||
| B R Brodeur | |||
| J Hamel | |||
| P2860 | cites work | Protein measurement with the Folin phenol reagent | Q20900776 |
| Topology of outer membrane porins in pathogenic Neisseria spp | Q24643005 | ||
| Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 | Q25938983 | ||
| Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors | Q26778475 | ||
| Use of T7 RNA polymerase to direct expression of cloned genes | Q27860692 | ||
| Sequence from picomole quantities of proteins electroblotted onto polyvinylidene difluoride membranes | Q28131700 | ||
| Killing of Neisseria meningitidis by human neutrophils: implications for normal and complement-deficient individuals | Q28290497 | ||
| Development, characterization, and biological properties of meningococcal immunotype L3,7,(8),9-specific monoclonal antibodies | Q28378767 | ||
| Construction of versatile low-copy-number vectors for cloning, sequencing and gene expression in Escherichia coli | Q29615309 | ||
| Cloning and expression in Escherichia coli of opc, the gene for an unusual class 5 outer membrane protein from Neisseria meningitidis (meningococci/surface antigen) | Q33311967 | ||
| Use of transformation to construct antigenic hybrids of the class 1 outer membrane protein in Neisseria meningitidis | Q33610780 | ||
| Clinical Efficacy of Meningococcus Group A Capsular Polysaccharide Vaccine in Children Three Months to Five Years of Age | Q34201570 | ||
| Persistence of antibody following immunization of children with groups A and C meningococcal polysaccharide vaccines | Q34202126 | ||
| Prevention of Meningococcal Disease by Group C Polysaccharide Vaccine | Q34225615 | ||
| Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccine in adults. | Q34533811 | ||
| Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine | Q34557991 | ||
| Expression of Neisseria meningitidis iron-regulated outer membrane proteins, including a 70-kilodalton transferrin receptor, and their potential for use as vaccines | Q35103809 | ||
| Monoclonal antibodies against the 70-kilodalton iron-regulated protein of Neisseria meningitidis are bactericidal and strain specific | Q35104508 | ||
| Human immunity to the meningococcus. I. The role of humoral antibodies | Q36269707 | ||
| Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers | Q36269725 | ||
| Human immunity to the meningococcus. II. Development of natural immunity | Q36269758 | ||
| Interaction of complement with Neisseria meningitidis and Neisseria gonorrhoeae | Q36633889 | ||
| Global epidemiology of meningococcal disease | Q36634411 | ||
| Immunological characterization of the lipooligosaccharide B band of Bordetella pertussis | Q36947250 | ||
| Construction of a multivalent meningococcal vaccine strain based on the class 1 outer membrane protein | Q36949061 | ||
| Mapping of B-cell epitopes on the outer membrane P2 porin protein of Haemophilus influenzae by using recombinant proteins and synthetic peptides | Q36962334 | ||
| Meningococcal vaccines—present and future | Q37013540 | ||
| Protection against infection with Neisseria meningitidis group B serotype 2b by passive immunization with serotype-specific monoclonal antibody. | Q37049370 | ||
| Monoclonal antibody that recognizes an outer membrane antigen common to the pathogenic Neisseria species but not to most nonpathogenic Neisseria species | Q37097514 | ||
| Serotype antigens of Neisseria meningitidis and a proposed scheme for designation of serotypes | Q38152331 | ||
| A sensitive silver stain for detecting lipopolysaccharides in polyacrylamide gels | Q39512862 | ||
| Meningococcal meningitis in the northern savanna of Africa | Q39590914 | ||
| Development of Antibodies to Meningococcal Protein and Lipopolysaccharide Serotype Antigens in Healthy Carriers | Q39656156 | ||
| Meningococcal Disease: Still with Us | Q40145726 | ||
| Preparation and immunochemical characterization of meningococcal group C polysaccharide-tetanus toxoid conjugates as a new generation of vaccines | Q40184073 | ||
| Importance of complement source in bactericidal activity of human antibody and murine monoclonal antibody to meningococcal group B polysaccharide. | Q40184215 | ||
| Mechanism of incorporation of cell envelope proteins in Escherichia coli | Q40248345 | ||
| Development of a meningococcal vaccine | Q40512734 | ||
| The meningococcal transferrin-binding proteins 1 and 2 are both surface exposed and generate bactericidal antibodies capable of killing homologous and heterologous strains | Q40958148 | ||
| Immunochemistry of groups A, B, and C meningococcal polysaccharide-tetanus toxoid conjugates. | Q41600899 | ||
| Detection of Neisseria gonorrhoeae by dot-enzyme immunoassay using monoclonal antibodies | Q44747675 | ||
| The antibody response to a prototype liposome vaccine containing Neisseria meningitidis outer membrane protein P1 produced in Bacillus subtilis | Q46971692 | ||
| Microevolution within a clonal population of pathogenic bacteria: recombination, gene duplication and horizontal genetic exchange in the opa gene family of Neisseria meningitidis | Q48083959 | ||
| Class 1 outer membrane protein of Neisseria meningitidis: epitope analysis of the antigenic diversity between strains, implications for subtype definition and molecular epidemiology | Q48136034 | ||
| Characterization of the opa (class 5) gene family of Neisseria meningitidis | Q48223983 | ||
| The 5C protein of Neisseria meningitidis is highly immunogenic in humans and induces bactericidal antibodies. | Q54282592 | ||
| Classification of Neisseria meningitidis Group B into Distinct Serotypes. III. Application of a New Bactericidal-Inhibition Technique to Distribution of Serotypes among Cases and Carriers | Q54651894 | ||
| Meningococcal Opa and Opc proteins: their role in colonization and invasion of human epithelial and endothelial cells. | Q55065744 | ||
| Heterohybridomas secreting human monoclonal antibodies against Haemophilus influenzae type b | Q64130265 | ||
| Antibodies to meningococcal H.8 (Lip) antigen fail to show bactericidal activity | Q67289873 | ||
| Human monoclonal antibodies against an epitope on the class 5c outer membrane protein common to many pathogenic strains of Neisseria meningitidis | Q67545520 | ||
| Blocking of bactericidal killing of Neisseria meningitidis by antibodies directed against class 4 outer membrane protein | Q67865762 | ||
| Bactericidal antibodies after vaccination with the Norwegian meningococcal serogroup B outer membrane vesicle vaccine: a brief survey | Q67885860 | ||
| Meningococcal serogroup B vaccine protection trial and follow-up studies in Chile. The Chilean National Committee for Meningococcal Disease | Q67885861 | ||
| Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C | Q68043168 | ||
| A monoclonal antibody directed against a serotype-specific, outer-membrane protein of Haemophilus influenzae type b | Q68989046 | ||
| Vaccines for prevention of meningococcal disease | Q69198474 | ||
| Comparative evaluation of potential components for group B meningococcal vaccine by passive protection in the infant rat and in vitro bactericidal assay | Q69247824 | ||
| Outer membrane proteins of Neisseria meningitidis: structure and importance in meningococcal disease | Q70298701 | ||
| Protective efficacy of monoclonal antibodies to class 1 and class 3 outer membrane proteins of Neisseria meningitidis B:15:P1.16 in infant rat infection model: new prospects for vaccine development | Q70413639 | ||
| Physicochemical and immunological characterization of meningococcal group A polysaccharide-tetanus toxoid conjugates prepared by two methods | Q70517771 | ||
| Measurement of antibodies to meningococcal group B polysaccharide: low avidity binding and equilibrium binding constants | Q71620228 | ||
| Construction of Neisseria meningitidis strains carrying multiple chromosomal copies of the porA gene for use in the production of a multivalent outer membrane vesicle vaccine | Q72339933 | ||
| Transferrin-binding proteins isolated from Neisseria meningitidis elicit protective and bactericidal antibodies in laboratory animals | Q72646033 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Neisseria meningitidis | Q154625 |
| experimental infection | Q107184421 | ||
| P304 | page(s) | 1173-1183 | |
| P577 | publication date | 1997-04-01 | |
| P1433 | published in | Journal of Experimental Medicine | Q3186912 |
| P1476 | title | Highly conserved Neisseria meningitidis surface protein confers protection against experimental infection | |
| P478 | volume | 185 |
| Q64106983 | A homopolymeric adenosine tract in the promoter region of nspA influences factor H-mediated serum resistance in Neisseria meningitidis |
| Q41636085 | A recombinant truncated surface immunogenic protein (tSip) plus adjuvant FIA confers active protection against Group B streptococcus infection in tilapia |
| Q36313869 | Additive and synergistic bactericidal activity of antibodies directed against minor outer membrane proteins of Neisseria meningitidis. |
| Q34001090 | Antigenic and molecular conservation of the gonococcal NspA protein |
| Q34001933 | Bactericidal and cross-protective activities of a monoclonal antibody directed against Neisseria meningitidis NspA outer membrane protein. |
| Q36710765 | Bactericidal antibody responses induced by meningococcal recombinant chimeric factor H-binding protein vaccines |
| Q30150784 | Can Neisseria lactamica antigens provide an effective vaccine to prevent meningococcal disease? |
| Q72989198 | Candidate Neisseria meningitidis NspA vaccine |
| Q37503243 | Challenges and progress in the development of a serogroup B meningococcal vaccine |
| Q41922489 | Characterization of Neisseria meningitidis isolates that do not express the virulence factor and vaccine antigen factor H binding protein |
| Q83061033 | Characterization of meningococcal serogroup B outer membrane vesicle vaccines from strain 44/76 after growth in different media |
| Q93184943 | Chimeric hepatitis B virus core particles displaying Neisserial surface protein A confer protection against virulent Neisseria meningitidis serogroup B in BALB/c mice |
| Q33729938 | Cloning and characterization of a gene encoding the major surface protein of the bacterial endosymbiont Wolbachia pipientis |
| Q39667409 | Comparative genome biology of a serogroup B carriage and disease strain supports a polygenic nature of meningococcal virulence |
| Q30164390 | Conformational epitopes recognized by protective anti-neisserial surface protein A antibodies |
| Q27641060 | Crystal Structure of Neisserial Surface Protein A (NspA), a Conserved Outer Membrane Protein with Vaccine Potential |
| Q34133149 | Development of natural immunity to Neisseria meningitidis |
| Q34623334 | Development of vaccines against meningococcal disease |
| Q34002334 | Differences in surface expression of NspA among Neisseria meningitidis group B strains. |
| Q37124721 | Does binding of complement factor H to the meningococcal vaccine antigen, factor H binding protein, decrease protective serum antibody responses? |
| Q48130502 | Evidence of positive Darwinian selection in putative meningococcal vaccine antigens |
| Q37582852 | Expression of heterologous antigens in commensal Neisseria spp.: preservation of conformational epitopes with vaccine potential. |
| Q38307883 | Expression of the iron-activated nspA and secY genes in Neisseria meningitidis group B by Fur-dependent and -independent mechanisms |
| Q38829564 | Fighting Neisseria meningitidis: past and current vaccination strategies |
| Q34007747 | Functional activity of anti-Neisserial surface protein A monoclonal antibodies against strains of Neisseria meningitidis serogroup B. |
| Q35946901 | Functional and specific antibody responses in adult volunteers in new zealand who were given one of two different meningococcal serogroup B outer membrane vesicle vaccines |
| Q39891660 | Identification and characterization of a novel outer membrane protein (OMP J) of Moraxella catarrhalis that exists in two major forms |
| Q33591531 | Identification of group B streptococcal Sip protein, which elicits cross-protective immunity |
| Q54458667 | Identification of new meningococcal serogroup B surface antigens through a systematic analysis of neisserial genomes. |
| Q46554450 | Identification of novel antigens that protect against systemic meningococcal infection |
| Q51930932 | Identifying candidate subunit vaccines using an alignment-independent method based on principal amino acid properties. |
| Q36513433 | Impaired Immunogenicity of Meningococcal Neisserial Surface Protein A in Human Complement Factor H Transgenic Mice |
| Q83294193 | Improved immunogenicity of a H44/76 group B outer membrane vesicle vaccine with over-expressed genome-derived Neisserial antigen 1870 |
| Q37120976 | Is gonococcal disease preventable? The importance of understanding immunity and pathogenesis in vaccine development |
| Q39764973 | Isolation and characterization of an antigen from the fish pathogen Moritella viscosa. |
| Q34002814 | Leptospiral outer membrane proteins OmpL1 and LipL41 exhibit synergistic immunoprotection. |
| Q48076533 | Lipoprotein NMB0928 from Neisseria meningitidis serogroup B as a novel vaccine candidate |
| Q37501041 | Meningococcal interactions with the host |
| Q37501047 | Meningococcal protein antigens and vaccines |
| Q34218569 | Meningococcal vaccines |
| Q80511370 | Meningococcal vaccines |
| Q33701334 | Mucosal immunity in the genital tract: prospects for vaccines against sexually transmitted diseases--a review |
| Q35530224 | Neisseria gonorrhoeae NspA induces specific bactericidal and opsonic antibodies in mice |
| Q37478314 | Neisseria lactamica antigens complexed with a novel cationic adjuvant |
| Q38183156 | Neisseria meningitidis B vaccines: recent advances and possible immunization policies. |
| Q37878480 | New frontiers in meningococcal vaccines |
| Q33361232 | Outer membrane vesicles (OMVs) and detoxified lipooligosaccharide (dLOS) obtained from Brazilian prevalent N. meningitidis serogroup B strains protect mice against homologous and heterologous meningococcal infection and septic shock |
| Q46560177 | Passive protection in the infant rat protection assay by sera taken before and after vaccination of teenagers with serogroup B meningococcal outer membrane vesicle vaccines |
| Q57793536 | Phase 1 first-in-human studies of the reactogenicity and immunogenicity of a recombinant meningococcal NspA vaccine in healthy adults |
| Q36464572 | Prevalence of factor H-binding protein variants and NadA among meningococcal group B isolates from the United States: implications for the development of a multicomponent group B vaccine |
| Q33202131 | Prevention of pneumococcal disease in mice immunized with conserved surface-accessible proteins |
| Q40711453 | Previously unrecognized vaccine candidates against group B meningococcus identified by DNA microarrays |
| Q24537338 | Prospects for vaccine prevention of meningococcal infection |
| Q74598037 | Protection against experimental infection with group B streptococcus by immunization with a bivalent protein vaccine |
| Q34004241 | Protection elicited by native outer membrane protein Oms66 (p66) against host-adapted Borrelia burgdorferi: conformational nature of bactericidal epitopes |
| Q36638451 | Protective antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed genome-derived neisserial antigen 1870 |
| Q42232579 | Proteomic analysis of outer membranes and vesicles from wild-type serogroup B Neisseria meningitidis and a lipopolysaccharide-deficient mutant. |
| Q33646965 | Review of meningococcal group B vaccines |
| Q34185172 | Sequential immunization with vesicles prepared from heterologous Neisseria meningitidis strains elicits broadly protective serum antibodies to group B strains |
| Q35648260 | Serologic correlates of protection for evaluating the response to meningococcal vaccines |
| Q30159962 | Solution structure of the immunodominant domain of protective antigen GNA1870 of Neisseria meningitidis |
| Q38606992 | Specificity of subcapsular antibody responses in Ethiopian patients following disease caused by serogroup A meningococci |
| Q54337514 | The design of new adjuvants for mucosal immunity to Neisseria meningitidis B in nasally primed neonatal mice for adult immune response. |
| Q28474974 | The meningococcal vaccine candidate neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complement |
| Q34712881 | The meningococcus tamed? |
| Q33936713 | The phasevarion: a genetic system controlling coordinated, random switching of expression of multiple genes |
| Q36327065 | Towards an improved serogroup B Neisseria meningitidis vaccine |
| Q40582738 | Vaccination with attenuated Neisseria meningitidis strains protects against challenge with live Meningococci |
| Q37115883 | Vaccine potential of the Neisseria meningitidis 2086 lipoprotein |
| Q34460367 | Vaccine prevention of meningococcal disease, coming soon? |
| Q38163516 | Vaccine research for gonococcal infections: where are we? |
| Q38350786 | Variation of the factor H-binding protein of Neisseria meningitidis |
Search more.